Dr. Bruix on the Phase III RESORCE Trial in HCC

Jordi Bruix, MD
Published: Saturday, Oct 08, 2016



Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

The trial assessed patients with HCC who had previously progressed on sorafenib. Patients were randomized 2:1 to receive regorafenib at 160 mg per day or placebo on weeks 1-3 of each 4-week cycle until progression, death, or unacceptable toxicity.

Overall survival (OS), which was the study's primary endpoint, was significantly improved, with a hazard ratio of 0.63, explains Bruix. The results demonstrated that regorafenib was active, efficacious, and provided clinically meaningful improvement in OS, says Bruix.


Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

The trial assessed patients with HCC who had previously progressed on sorafenib. Patients were randomized 2:1 to receive regorafenib at 160 mg per day or placebo on weeks 1-3 of each 4-week cycle until progression, death, or unacceptable toxicity.

Overall survival (OS), which was the study's primary endpoint, was significantly improved, with a hazard ratio of 0.63, explains Bruix. The results demonstrated that regorafenib was active, efficacious, and provided clinically meaningful improvement in OS, says Bruix.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x